The role of bisphosphonates in early breast cancer

Oncologist

Volumn 11, Issue SUPPL. 1, 2006, Pages 13-19

  Paterson, Alexander H G ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adjuvant; Bisphosphonates; Bonemetastases; Ibandronate; Skeletal related event

Indexed keywords

4 HYDROXYTAMOXIFEN; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; FULVESTRANT; IBANDRONIC ACID; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADJUVANT THERAPY; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE REMODELING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONFERENCE PAPER; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EYE TOXICITY; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; BONE TUMOR; BREAST TUMOR; CANCER STAGING; CLASSIFICATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE REMODELING; BREAST NEOPLASMS; CLINICAL TRIALS; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM STAGING;

EID: 35648968643     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-90001-13     Document Type: Conference Paper

References (42)

1. Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol 2002;29(suppl 11):134-144.
2. van der Pluijm G, Vloedgraven H, van Beek E et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705.
3. Neudert M, Fischer C, Krempien B et al. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer 2003;107:468-477.
4. Wood J, Bonjean K, Ruetz S et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061.
5. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-1664.
6. Mundy GR. Mechanisms of bone metastasis. Cancer 1997;80(8 suppl):1546-1556.
7. Paterson AH, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
8. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791.
9. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17:846-854.
10. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
11. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-1405.
12. Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133-1137.
13. Bauss F. Body JJ. Ibandronate in metastatic bone disease: a review of pre-clinical data. Anticancer Drugs 2005;16:107-118.
14. Boissier S, Magnetto S, Frappart L et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;57:3890-3894.
15. Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-2954.
16. Fournier P, Boissier S, Filleur S et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-6544.
17. Fromigue O, Kheddoumi N, Body JJ. Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. Br J Cancer 2003;89:178-184.
18. Senaratne SG, Pirianov G, Mansi JL et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-1468.
19. Hiraga T, Williams PJ, Mundy GR et al. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001;61:4418-4424.
20. Jagdev SP, Coleman RE, Shipman CM et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001;84:1126-1134.
21. Neville-Webbe HL, Evans CA, Coleman RE et al. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006;27:92-103.
22. Magnetto S, Boissier S, Delmas PD et al. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int I Cancer 1999;83:263-269.
23. JourneF, Chaboteaux C, Magne N et al. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast can cer cell lines. Breast Cancer Res 2005;8:R2.Epub 2005 Dec 12.
24. Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-363.
25. Jaschke A, Bastert G, Solomayer EF et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up. Proc Am Soc Clin Oncol 2004;23:9.
26. Saarto T, Blomqvist C, Virkkunen P et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10-17.
27. Powles T, Paterson S. Kanis JA et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219-3224.
28. Powles T, Paterson A, McCloskey E et al. Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. Proc Am Soc Clin Oncol 2004;23:9.
29. Kokufu I, Kohno N, Takao S etal. Adjuvant pamidronate (PMT) therapy for the prevention of bone metastasis in breast cancer (BC) patients (pts) with four or more positive nodes. Proc Am Soc Clin Oncol 2004;23:9.
30. Mystakidou K, Katsouda E, Parpa E et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005;22:195-201.
31. Saarto T, Vehmanen L, Virkkunen P et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004;43:650-656.
32. Diel IJ, Solomayer E, Gollan C et al. Bisphosphonates in the reduction of metastases in breast cancer-results of the extended follow-up of the first study population. Proc Am Soc Clin Oncol 2000;19:82a.
33. Gralow J, Paterson A. S0307: a phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer. Bone 2006;38(suppl 1):S74.
34. Mian M. Beghe F, Caprio A et al. Tolerability and safety of clodronate therapy in bone diseases. Int J Clin Pharmacol Res 1991;11:107-114.
35. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. I Clin Oncol 1995;13:2427-2430.
36. Body JJ, Kanis J, Diel I et al. Risk reductions in metastatic breast cancer: multivariate Poisson regression analyses of oral and i.v. ibandronate. Proc Am Soc Clin Oncol 2003;22:46.
37. Tripathy D, Budde M. Assessing the efficacy of ibandronate for the prevention of skeletal-related events (SREs) in metastatic bone disease: a methodological comparison. Bone 2004;34(suppl 1):S91.
38. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-1679.
39. Johnson KB, Gable P, Kaime EM et al. Significant deterioration in renal function with the new bisphosphonate. zoledronic acid. Proc Am Soc Clin Oncol 2003;22:46.
40. Migliorati CA, Schubert MM, Peterson DE et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
41. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
42. Coleman R, Gralow J, Bell R et al. Zoledronic acid is being investigated for the prevention of bone metastases in patients with early stage breast cancer. Bone 2004;34(suppl 1):S85.